Phase 3 trial results showed that adding veliparib to temozolomide did not significantly improve overall or progression-free survival in newly diagnosed, MGMT-hypermethylated glioblastoma.
Home phlebotomy is increasingly being considered for patients with cancer to improve access to standard care and investigational treatments by reducing time toxicity, according to researchers.